PAPER Zhou D, Zhang M, Ye X, Gu C, Piser TM, Lanoue BA, Schock SA, Cheng YF, Grimm SW
SEARCH RESULTS
331397 RESULTS
PAPER Choi SH, Li Y
Elevated levels of BMP6 impair neurogenesis in Alzheimer's disease.
J Neurosci. 2011 Jan 12;31(2):371-2. PubMed: 21228148PAPER Krueger F, Pardini M, Huey ED, Raymont V, Solomon J, Lipsky RH, Hodgkinson CA, Goldman D, Grafman J
The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combat-related traumatic brain injury.
J Neurosci. 2011 Jan 12;31(2):598-606. PubMed: 21228168PAPER Hefendehl JK, Wegenast-Braun BM, Liebig C, Eicke D, Milford D, Calhoun ME, Kohsaka S, Eichner M, Jucker M
Long-term in vivo imaging of β-amyloid plaque appearance and growth in a mouse model of cerebral β-amyloidosis.
J Neurosci. 2011 Jan 12;31(2):624-9. PubMed: 21228171PAPER Hongpaisan J, Sun MK, Alkon DL
PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice.
J Neurosci. 2011 Jan 12;31(2):630-43. PubMed: 21228172PAPER Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
J Neurosci. 2011 Jan 12;31(2):700-11. PubMed: 21228179PAPER Breitner JC
Apolipoprotein e, Alzheimer's disease, and amyloid: do we have the cart before the horse?
J Alzheimers Dis. 2011;23(1):171-2. PubMed: 21228459PAPER
Upcoming meetings related to Alzheimer's disease.
Rev Neurol. 2011 Jan 16;52(2):101-111. PubMed: 21228460PAPER Hori K, Konishi K, Watanabe K, Uchida H, Tsuboi T, Moriyasu M, Tominaga I, Hachisu M
Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer's disease.
Neuropsychobiology. 2011;63(3):147-53. PubMed: 21228606PAPER Baek MJ, Kim HJ, Ryu HJ, Lee SH, Han SH, Na HR, Chang Y, Chey JY, Kim S
The usefulness of the story recall test in patients with mild cognitive impairment and Alzheimer's disease.
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2011 Mar;18(2):214-29. PubMed: 21229403PAPER Gallagher D, Coen R, Kilroy D, Belinski K, Bruce I, Coakley D, Walsh B, Cunningham C, Lawlor BA
Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment.
Int J Geriatr Psychiatry. 2011 Feb;26(2):166-72. PubMed: 21229599PAPER Supprian T, Höhl W
[Treatment of dementia].
MMW Fortschr Med. 2010 Nov 4;152(44):54-7; quiz 58. PubMed: 21158177PAPER Blesa González R, Boada Rovira M, Martínez Parra C, Gil-Saladié D, Almagro CA, Gobartt Vázquez AL,
Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
Neurologia. 2011 Jun;26(5):262-271. PubMed: 21227548PAPER Papaliagkas VT, Kimiskidis VK, Tsolaki MN, Anogianakis G
Cognitive event-related potentials: longitudinal changes in mild cognitive impairment.
Clin Neurophysiol. 2011 Jul;122(7):1322-6. PubMed: 21227748PAPER Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.
Neurology. 2011 Feb 8;76(6):501-10. PubMed: 21228296Current Filters
No filters selected